Menu
ncarol.com
  • Home
  • Financial
  • Education
  • Business
  • Banking
  • Nyse
  • Finance
  • Yacht Buyer
  • Stocks
ncarol.com

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
ncarol.com/10212254

Trending...
  • Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
  • Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

More on ncarol.com
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Craigory Dunn & Dre Barracks Release Gospel-Soul Collaboration The Soul Renaissance
  • Why Screen-Fatigued Parents are Choosing the Human Bridge
  • Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Investor Contact:

Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
  • Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
  • Global Window Covering Industry Pros and Designers Head to Raleigh for Major Trade-Only Expo
  • RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
  • Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
  • Stonewood Cottage Coworking Nominated for Best Coworking Space in the Best of North Carolina Awards
  • Grads aren't getting hired — here's what we're doing about it
  • MetalMetric Launches Free Live Precious Metals Melt Value Calculator Suite
  • K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
  • #WeAreGreekWarriors Comes to Detroit in Celebration of Women's History Month
  • Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
  • Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
  • The Franchise King® Releases Free Guide for Nervous Buyers
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
  • Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
_catLbl0 _catLbl1

Popular on ncarol.com

  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies - 122
  • Still Using Ice? FrostSkin Reinvents Hydration - 111
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
  • Cold. Clean. Anywhere. Meet FrostSkin
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
  • Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract

Similar on ncarol.com

  • $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
  • Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
  • $6 Million Funding Secured as Retail Expansion, Operational Streamlining, and Asset-Light Strategy Position the Company for Accelerated Growth $SOWG
  • The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
  • Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
  • K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
  • Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
  • Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
  • The Franchise King® Releases Free Guide for Nervous Buyers
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute